Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ricky Sandler, Eminence Capital Think Aeropostale is a Buy

Ricky Sandler, Eminence Capital: Ricky Sandler’s Eminence Capital recently disclosed ownership of 4.2 million shares of Aeropostale Inc (NYSE:ARO), which shows an increase by 1.2 million shares, according to a filing with the Securities and Exchange Commission. The stake represents 5.4% of the company, and has a value of $39.2 million, at the current price of Aeropostale’s stock.

Ricky Sandler

The net sales of Aeropostale declined by 6% in year-on-year terms, and amounted to $454 million last quarter, versus $485.3 million reported for the same period of last year. The company also declared a net loss of $33.7 million, which is equal to $0.43 per share. For the current quarter, Aeropostale forecasts a net loss of $0.21 to $0.26 per diluted share, in comparison to a profit of $0.31 reported for the third quarter of 2012.

Aside from Eminence Capital, some other hedge funds out of those we track also reported owning shares of Aeropostale in the latest round of 13F filings. Scopia Capital, managed by Matt Sirovich and Jeremy Mindich, disclosed ownership of more than 4.9 million shares, while Patrick Mccormack’s Tiger Consumer Management‘s stake contained 3.6 million shares at the end of last quarter. And the last but not the least is Pzena Investment Management, managed by Richard S. Pzena, which held some 2.2 million shares of Aeropostale.

Recommended Reading:

Kyle Bass, Hayman Advisors Are Bullish on PennyMac Mortgage Investment

Is Synageva BioPharma a Buy? Baker Bros. Thinks So

Glenn Greenberg, Brave Warrior Capital Reduce Higher One Stake

Disclosure: none

Loading...